drugset / Trial / NCT04009876

A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer

NCT04009876

Phase 2 Completed 30 enrolled HM Hospitales Syntax for Science, S.L · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an exploratory, open-label, single arm, non-randomized, multicenter, phase II clinical trial to determine the efficacy and clinical complete response rate in patients with rectal cancer and tumor preoperative evaluation after NAC (Neoadjuvant Chemotherapy) with NALIRINOX (5-FU \[fluorouracil)/LV \[Leucovorin calcium\] + oxaliplatin + nal-IRI \[Liposomal Irinotecan\]) and chemoradiotherapy.

Timeline

Start
2019-05-01
Primary completion
2022-10-21
Completion
2022-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Sucrosofate Other / unclassified
Subject Leucovorin Small molecule
Subject Oxaliplatin Small molecule
Subject fluorouracil Small molecule

Indications